Clinical TrialID 8190

PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

NCT05906511

Pain, Tolerance|Oral vs Vaporized THC|Abuse Liability

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
8190
Evidence Id
8190
Core Evidence Id
8190
Source Clinical Trial Id
8188
Herb2 Clinical Trial Id
HBCT008188
Nct Id
NCT05906511
Title
PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults
Status
Recruiting
Phase
Early_Phase 1
Study Result
No
Study Condition
Pain, Tolerance|Oral vs Vaporized THC|Abuse Liability
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER
Intervention
DRUG: Dronabinol 5 MG|DRUG: Dronabinol 10 MG|DRUG: 2mg Purified THC in an ethanolic solution|DRUG: 4mg Purified THC in an ethanolic solution|DRUG: Placebo
Intervention Allocation
Randomized
Intervention Model
Crossover
Intervention Mask
Double
Intervention Purpose
Other
Gender
All
Age
Older_Adult
Enrollment
30
Outcome Measure
Peak concentration (Cmax), Serial blood samples will be collected for plasma levels of THC; its phase I metabolite 11-hydroxy-THC (OH-THC); phase II metabolite 11-nor-9-carboxy-THC (THC-COOH); and THC-COOH glucuronide. For THC and all other analytes, the peak concentration (Cmax) will be derived using a linear noncompartmental analysis., Up to 8 hours|Time to attain Cmax concentration (Tmax), Serial blood samples will be collected for plasma levels of THC; its phase I metabolite 11-hydroxy-THC (OH-THC); phase II metabolite 11-nor-9-carboxy-THC (THC-COOH); and THC-COOH glucuronide. For THC and all other analytes, the time to attain Cmax concentration (Tmax) will be derived using a linear noncompartmental analysis., Up to 8 hours|Area under the plasma concentration-time curve (AUC0-8h), Serial blood samples will be collected for plasma levels of THC; its phase I metabolite 11-hydroxy-THC (OH-THC); phase II metabolite 11-nor-9-carboxy-THC (THC-COOH); and THC-COOH glucuronide. For THC and all other analytes, the area under the plasma concentration-time curve (AUC0-8h) will be derived using a linear noncompartmental analysis., Up to 8 hours|Nociception, Multimodal quantitative sensory testing (QST) will be used ensure that various types of afferent fibers are engaged, so that the analgesic efficacy of THC can be comprehensively investigated. A composite pain sensitivity measure as a Z-score (ranging from -1 to +1) will be derived from the QST battery, with greater scores indicating a higher sensitivity to pain., Up to 8 hours|Abuse Liability, A modified Multiple-Choice Procedure (MPC) will be used to measure abuse liability. The MCP was developed and validated by Roland Griffiths to efficiently assess drug reinforcement - including cannabinoid-induced reinforcement. In each of the 6 experimental sessions, participants will choose between forfeiting or receiving escalating sums of money, on a scale of values between -$20.00 and $20.00; or re-receiving the study medication assigned for that day. The primary outcome will be the crossover point, the value at which the participant chooses money rather than the study medication, which will be determined for each session., Up to 8 hours
Sponsor Collaborator
Yale University|VA Connecticut Healthcare System|National Institute on Drug Abuse (NIDA)
Funded By
OTHER
Location
VA Connecticut Healthcare System, West Haven, Connecticut, 06516, United States
Other Id
2000035354|1R21DA057240-01
Start Date
2023-10-17
Primary Completion Date
2025-04-30
Completion Date
2025-04-30
First Posted
2023-06-18
Results First Posted
Last Update Posted
2024-01-23
Study Document
Study Url
https://clinicaltrials.gov/study/NCT05906511
Title Cn
Title En
PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults
Bilingual Status
semi_complete